Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) Equity Average (2022 - 2025)

Historic Equity Average for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $263.7 million.

  • Zentalis Pharmaceuticals' Equity Average fell 2843.53% to $263.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $263.7 million, marking a year-over-year decrease of 2843.53%. This contributed to the annual value of $387.3 million for FY2024, which is 1111.27% down from last year.
  • As of Q3 2025, Zentalis Pharmaceuticals' Equity Average stood at $263.7 million, which was down 2843.53% from $284.9 million recorded in Q2 2025.
  • Over the past 5 years, Zentalis Pharmaceuticals' Equity Average peaked at $502.6 million during Q3 2023, and registered a low of $263.7 million during Q3 2025.
  • For the 4-year period, Zentalis Pharmaceuticals' Equity Average averaged around $396.5 million, with its median value being $415.3 million (2023).
  • As far as peak fluctuations go, Zentalis Pharmaceuticals' Equity Average skyrocketed by 1527.71% in 2023, and later crashed by 3226.65% in 2025.
  • Zentalis Pharmaceuticals' Equity Average (Quarter) stood at $431.4 million in 2022, then grew by 6.55% to $459.6 million in 2023, then decreased by 24.78% to $345.8 million in 2024, then decreased by 23.74% to $263.7 million in 2025.
  • Its Equity Average stands at $263.7 million for Q3 2025, versus $284.9 million for Q2 2025 and $316.3 million for Q1 2025.